2013 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/19/13European Medicines Agency (EMA) Continues Marketing Authorization Application (MAA) Review for Lymphoseek®Download PDF
12/17/13Navidea Biopharmaceuticals Submits Supplemental New Drug Application (sNDA) for Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck CancerDownload PDF
12/10/13FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck CancerDownload PDF
12/03/13Navidea Biopharmaceuticals Initiates Pivotal Phase 3 Registration Program of NAV5001 SPECT Imaging Agent for Parkinson’s DiseaseDownload PDF
12/02/13Navidea Biopharmaceuticals to Host Analyst Science Day December 5, 2013 in New York CityDownload PDF
11/26/13Navidea to Collaborate with University of Alabama–Birmingham on Clinical Study Evaluating the RIGS™ Monoclonal Antibody Targeting AgentDownload PDF
11/15/13Navidea Biopharmaceuticals Adds New Member to Board of DirectorsDownload PDF
11/14/13Navidea Biopharmaceuticals Announces Issuance of New U.S. Patent Covering Formulation for Neuroimaging Agent, NAV5001Download PDF
11/13/13Navidea to Collaborate with University of California–San Francisco on Clinical Study Evaluating Manocept™ Platform Imaging Agent in Kaposi Sarcoma (KS) PatientsDownload PDF
11/06/13Navidea Biopharmaceuticals Announces Third Quarter 2013 ResultsDownload PDF
10/30/13Navidea Biopharmaceuticals Schedules Third Quarter 2013 Financial Results Conference CallDownload PDF
10/24/13Navidea Biopharmaceuticals Manocept™ Platform Featured in Nature Outlook: Medical ImagingDownload PDF
10/23/13Navidea Biopharmaceuticals Reiterates Position on Recent Financing, Stock PriceDownload PDF
10/16/13SAVE THE DATE: Navidea Biopharmaceuticals to Host Analyst Science Day December 5, 2013 in New York CityDownload PDF
10/07/13Navidea Biopharmaceuticals Announces Additional Results from Lymphoseek® Phase 3 Clinical Trial in Head and Neck Cancer at American College of Surgeons 2013 Annual Clinical CongressDownload PDF
09/24/13Navidea Biopharmaceuticals to Present at BioCentury’s NewsMakers in the Biotech Industry ConferenceDownload PDF
09/24/13Navidea Biopharmaceuticals Completes $30 Million Registered Direct Offering of Common StockDownload PDF
09/19/13Independent Investigators Report Lymphoseek® Results in JAMA Otolaryngology Head and Neck SurgeryDownload PDF
09/19/13Navidea Biopharmaceuticals Presents New Data on Precision Diagnostic Platform at Harvard ConferenceDownload PDF
09/04/13Navidea Awarded an Additional NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent for Study in Mild Cognitive ImpairmentDownload PDF
08/22/13Navidea Biopharmaceuticals Announces Agreement with FDA on Special Protocol Assessments for NAV5001 Phase 3 ProgramDownload PDF
08/21/13Navidea Awarded NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent Phase 3 Clinical Program Aimed at Alzheimer’s DiseaseDownload PDF
08/21/13Navidea Biopharmaceuticals Signs Manufacturing Agreement with Siemens’ PETNET Solutions for NAV4694 Beta-amyloid Imaging AgentDownload PDF
08/20/13Navidea Biopharmaceuticals Announces Centers for Medicare & Medicaid Services (CMS) Issuance of Lymphoseek® Reimbursement Pass-Through C Code, Effective as of October 1, 2013Download PDF
08/07/13Navidea Biopharmaceuticals Announces Second Quarter 2013 ResultsDownload PDF
07/25/13Navidea Biopharmaceuticals to Announce Second Quarter 2013 Financial Results Pre-market on Wednesday, August 7, 2013Download PDF
07/22/13Navidea Biopharmaceuticals Highlights New Data for NAV4694 PET β-Amyloid Imaging Agent Presented at AAIC 2013Download PDF
07/16/13Navidea Biopharmaceuticals’ NAV4694 β-Amyloid Imaging Agent to Be Used in Alzheimer’s Disease Studies by Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL)Download PDF
07/15/13Navidea Biopharmaceuticals Announces Board Member ResignationDownload PDF
07/11/13Navidea Biopharmaceuticals to Co-Sponsor Alzheimer’s Imaging Consortium at Alzheimer’s Association International ConferenceDownload PDF
07/02/13Navidea Biopharmaceuticals to Present at the JMP Securities Healthcare ConferenceDownload PDF
06/27/13Navidea Biopharmaceuticals Announces 2013 Annual Meeting ResultsDownload PDF
06/27/13Navidea Biopharmaceuticals Initiates Enrollment in Global Phase 3 Trial of NAV4694 PET Imaging AgentDownload PDF
06/26/13Navidea Biopharmaceuticals Closes $25 Million Debt Financing with GE Capital, Healthcare Financial ServicesDownload PDF
06/12/13Navidea Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Lymphoseek® and ACOSOG Radiolabeled Colloid in Head and Neck CancerDownload PDF
06/11/13Navidea Biopharmaceuticals Announces Results from Lymphoseek® Study on Accuracy of Lymph Node Detection from Injection Time to SurgeryDownload PDF
06/10/13Navidea Biopharmaceuticals Announces Presentation of Results from Two Lymphoseek® and Radiolabeled Colloid Studies in Lymphatic Mapping for Breast Cancer at SNMMIDownload PDF
06/04/13Navidea Announces Data Presentations at 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)Download PDF
05/29/13Navidea Biopharmaceuticals Announces Highlights of Lymphoseek® Data Presented at Joint International Oncology Congress (JIOC)Download PDF
05/29/13Navidea Biopharmaceuticals to Present at the Jefferies 2013 Global Healthcare ConferenceDownload PDF
05/22/13Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Joint International Oncology Congress (JIOC)Download PDF
05/15/13Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with NordionDownload PDF
05/08/13Navidea Biopharmaceuticals Announces First Quarter 2013 ResultsDownload PDF
05/03/13Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013Download PDF
05/01/13Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek®Download PDF
04/25/13Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare ConferenceDownload PDF
04/24/13Navidea Biopharmaceuticals Announces Underwritten Sale of Common StockDownload PDF
04/18/13Navidea Biopharmaceuticals Announces that Results of NAV4694 Clinical Trial Published in the Journal of Nuclear MedicineDownload PDF
04/11/13Navidea's Presentation of Top-Line Interim Analysis of Lymphoseek® Head and Neck Phase 3 Trial Selected for Investigator AwardDownload PDF
04/05/13Navidea Biopharmaceuticals Retains Stern IR for Investor Relations ServicesDownload PDF
04/04/13Navidea Biopharmaceuticals Announces Positive Top-Line Results from Interim Analysis of Lymphoseek® Phase 3 Clinical Trial in Head and Neck CancerDownload PDF
04/03/13Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical TrialDownload PDF
04/01/13Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry ConferenceDownload PDF
03/27/13Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)Download PDF
03/21/13Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical OncologyDownload PDF
03/13/13Navidea Biopharmaceuticals to Hold Conference Call to Discuss Lymphoseek FDA ApprovalDownload PDF
03/13/13FDA Approves Navidea’s Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic MappingDownload PDF
03/06/13Navidea Announces Fourth Quarter and Full-Year 2012 ResultsDownload PDF
03/04/13Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013Download PDF
02/28/13Navidea Biopharmaceuticals to Present at the Cowen & Company 33rd Annual Health Care ConferenceDownload PDF
02/19/13Navidea Biopharmaceuticals to Present at the Citi 2013 Global Healthcare ConferenceDownload PDF
02/07/13Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific MeetingsDownload PDF
02/06/13Navidea Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor ConferenceDownload PDF
02/05/13Navidea Biopharmaceuticals Participates in Symposium Focused on Sentinel Lymph Node Biopsy at the International Symposium on Metastasis in Head and Neck CancerDownload PDF
02/04/13Navidea to Collaborate with Maimonides Medical Center on Clinical Trial Utilizing Lymphoseek® for Lymphatic Mapping in Colorectal CancerDownload PDF
01/30/13Navidea Biopharmaceuticals Announces Underwritten Sale of Common StockDownload PDF
01/15/13Navidea Biopharmaceuticals Announces Completion of Additional Fundamental Clinical Trial for Radiopharmaceutical Agent, NAV4694, in Alzheimer’s DiseaseDownload PDF
01/03/13Navidea Biopharmaceuticals Reaches Interim Analysis Point of Phase 3 Head and Neck Cancer Study of Lymphoseek®Download PDF
01/02/13Navidea Biopharmaceuticals Announces Presentation at the 2013 Biotech Showcase™ ConferenceDownload PDF